62 results about "Non specific" patented technology

Embodiments of the present invention generally relate to novel immunostimulatory compositions of use to stimulate non-specific immune responses in a subject. In certain embodiments, immunogenic compositions disclosed herein can be directed to use in the eye of a subject. In some embodiments, the immunogenic compositions disclosed herein enhance non-specific immune responses in the eye of a subject to treat or reduce the risk of onset of an eye condition. In other embodiments, compositions disclosed herein can be used to treat eye infections due to a microorganism, tumors of the eye, as well as, chronic wounds or infections of the eye. In some embodiments, immunogenic ocular formulations disclosed herein include combinations of agents for prolonged exposure to the eye for improved outcomes.

A method and kit are provided for detecting anti-drug antibodies (ADAs) against self-assembling trimeric biologics, such as XPro1595, a pegylated variant of soluble human Tumor Necrosis Factor, in biological samples, particularly human serum. The method employs an Affinity Capture Elution-Protein A / G (ACE-AG) assay that overcomes non-specific reagent interactions inherent in conventional bridging and standard ACE assays due to the biologic's dynamic monomer exchange. The assay utilizes a two-plate system: a streptavidin-coated plate with biotinylated trimeric biologic captures ADAs, which are eluted, neutralized, and transferred to a protein A / G-coated plate for specific immunoglobulin capture and detection with a sulfo-tagged trimeric biologic via electrochemiluminescence. The kit includes pre-coated plates, labeled biologics, elution and neutralization solutions, assay buffer, confirmatory reagent, and instructions. The assay offers a robust, specific, and sensitive solution for immunogenicity testing of trimeric biologics.

The application provides a multifunctional nano particle for targeting abdominal aortic aneurysm and a preparation method and application thereof, and belongs to the field of nanobiomedicine, wherein polyphenol oxidation self-polymer nanoparticles are used as carriers, doxycycline is loaded, and a targeting ligand cRGD is modified on the surface of the nano carrier; the neovasculature in the media and adventitia of AAA sites helps accumulation of the nanoparticles in the abdominal aortic aneurysm, and the integrin αν3 beta receptor highly expressed on the surface of the diseased cell membrane can recognize the cRGD with high affinity, and then mediate the targeted endocytosis of the nanoparticles; after intravenous injection, the nanoparticles can be effectively enriched in the lesion site and achieve long-term retention, and can release DC in response to the high ROS level in the tumor microenvironment; the drug is rapidly released to take effect, and the non-specific toxic side effects are reduced; the free radical scavenging capacity of the nanoparticles can be synergized with the DC activity to treat AAA through multiple mechanisms such as anti-inflammatory, antioxidant, macrophage repolarization promotion, anti-apoptosis and calcification inhibition, and MMPs inhibition.

The present application relates to the technical field of biomedicine, and in particular to a glutamate urea compound, a preparation method and a use thereof, a nuclide targeting probe, a preparation method and a use thereof, and a pharmaceutical composition. The glutamate urea compound and the nuclide targeting probe provided by the present application have excellent in vivo biological properties, high specific uptake in lesions having high PSMA protein expression, high target-to-non-target ratio, low non-specific background activity, and significantly enhanced tumor uptake and retention time, are suitable for use as nuclide treatment and imaging of tumors, can also reduce unnecessary radioactive damage to normal tissues and organs, can overcome the defects of relatively low target organ uptake and excessively short retention time of small molecules acting on PSMA, exhibit improved targeted PSMA nuclide treatment and imaging effects, and have the potential for clinical promotion and application.

The invention relates to the technical field of biomedical treatment, in particular to a primer probe combination for distinguishing and relatively quantifying wild type and secondary drug-resistant mutation of EGFR (Epidermal Growth Factor Receptor) genes. The ARMS PCR primer probe combination, the detection reagent, the kit and the detection method which take the EGFR gene as the target are obtained by optimizing the mutation site position and concentration of the primer probe and screening the annealing temperature and enzyme. The primer probe combination, the detection reagent, the kit and the detection method disclosed by the invention are used for ARMS PCR detection of EGFR genes, the amplification inhibition capability on a wild type template is improved, non-specific amplification is reduced to improve specificity, and meanwhile, a good linear relationship can be kept; the primer design process is simplified, and introduction of extra mismatched bases is avoided; a reliable relative quantitative system is established, experimental interference factors are eliminated, and abundance of mutant genes is accurately reflected; the detection period is shortened, the cost is reduced, clinical rapid detection requirements are met, and a more reliable technical means is provided for detection of mutant genes.

According to the DUX4-IGH rearrangement detection primer probe set, the kit and the application, common rearrangement fracture sites of DUX4-IGH are confirmed, an upstream primer is designed on the upstream of a DUX4 transcript, 33 downstream primers are designed according to IGH fracture positions, a universal primer is designed on the upstream of DUX4, and a universal DUX4 probe is designed near the downstream of the primer; interference between the primer probes is small, influence of non-specific amplification is small, the primer probes are suitable for specific detection of multiple DUX4-IGH rearrangement sites, the problem that rearrangement detection is difficult in the prior art is solved, DUX4-IGH fusion transcripts and ABL1 reference genes can be quantitatively detected in a digital PCR instrument through RT-PCR, a basis is provided for auxiliary diagnosis, and the primer probes have remarkable application prospects.

This invention provides a respiratory compensation early warning method and system based on multi-modal behavioral evolution recognition, comprising: continuously acquiring patient behavioral posture data; analyzing the behavioral posture data based on a predefined behavioral evolution knowledge base to identify whether there is a type I posture or a type II posture, wherein the type I posture is a high-frequency non-specific posture that exceeds the individual baseline, and the type II posture is a specific compensatory posture that conforms to a preset specific physiological definition; analyzing the temporal correlation between type I and type II postures, and generating a high-confidence early warning signal if an evolution from type I posture to type II posture is identified. This invention achieves a digital closed loop of clinical cognition: for the first time, it transforms the complete clinical cognition of medical staff—"the patient first becomes restless, then becomes short of breath and sits up"—into a calculable and predictable technical model, which is highly consistent with clinical thinking and easily trusted.

The invention relates to the technical field of molecular biological detection, in particular to a primer probe group and a kit for simultaneously detecting 21 respiratory tract pathogens in a sample and application of the primer probe group and the kit. The primer probe group comprises primer probe sequences as shown in SEQ ID NO. 1 to SEQ ID NO. 75. The primer probe group comprises primer probe sequences as shown in SEQ ID NO. According to the kit, 21 respiratory tract pathogens are detected through seven groups of detection, the total time consumption is about 45 minutes per batch, the detection time is shortened, and the kit has excellent specificity and no non-specific amplification and better meets the requirements of outpatient emergency treatment and fever outpatient service for rapid diagnosis.

The present invention relates to the field of biological detection technology, and in particular to a detection kit and method for eliminating nonspecific reactions in blood samples. The present invention provides a detection kit comprising a first reagent and a second reagent; the first reagent comprises a buffer solution, 0.01-0.5wt% sodium alginate, 0.05-1wt% nonionic surfactant, and 0.001-0.1wt% animal serum; the pH value of the first reagent buffer system is 7.2-7.4; the second reagent comprises an antibody buffer solution labeled with latex microspheres; the pH value of the second reagent buffer system is 7.8-8.0. The present invention provides a detection kit and its application, which can effectively eliminate the interference of nonspecific reactions on the detection results of biochemical indicators by using latex immunoturbidimetry to detect biochemical indicators in serum and plasma, thereby improving the accuracy of the detection results of biochemical indicators.

The invention relates to the technical field of novel drug application of compounds, in particular to a compound Man-Tz, a biological orthogonal reaction system and application of the compound Man-Tz. The dTRIM24 is accurately released at the atherosclerotic plaque through a biological orthogonal targeting technology, and the problem of non-specific distribution caused by a traditional administration mode is effectively solved by utilizing the specific reaction of an artificial target point Man-Tz and TCO-dTRIM24-TCO. According to the technology, the TRIM24 protein of 117kDa can be specifically degraded, and macrophages are promoted to be polarized to an anti-inflammatory M2 type by inhibiting Stat6 acetylation, so that plaque formation is inhibited. Experiments prove that the system has concentration and time-dependent effects, drug exposure of non-target tissues is remarkably reduced while efficient degradation activity is maintained, and a novel targeted therapy strategy with high specificity and low toxic and side effects is provided for atherosclerosis treatment.

The invention belongs to the technical field of animal pathogen molecular biology, and particularly relates to a dual quantitative fluorescent primer probe composition, a kit and an identification method for identifying hog cholera virus. Aiming at the current popular strains covering 3 genotypes, 11 gene subtypes and the like of the hog cholera gene, the invention selects 5UTR and NS3 gene sequences of hog cholera virus to design and synthesize specific primers and probes aiming at the two fragments; the specific primer has no non-specific amplification on African swine fever virus, pseudorabies virus, porcine reproductive and respiratory syndrome virus, porcine circovirus type II, porcine epidemic diarrhea and bovine viral diarrhea. The invention establishes a method for identifying the classical swine fever virus wild strain and the vaccine strain and develops a kit convenient for diagnosis, and the kit and the identification method can simultaneously identify the classical swine fever virus wild strain and the vaccine strain, have the characteristics of high sensitivity, strong specificity, good repeatability and good stability, and have extremely strong application prospects.

This invention relates to the field of biological detection, and more particularly to a monoclonal antibody combination for detecting human IL-8 protein and its application. The combination comprises monoclonal antibodies 2G3 and 3H8. The heavy and light chain variable regions of monoclonal antibody 2G3 include the complementarity-determining regions shown in SEQ ID NO. 1-6; the heavy and light chain variable regions of monoclonal antibody 3H8 include the CDRs shown in SEQ ID NO. 7-12. The antibody combination of this invention exhibits high specificity and effectively avoids cross-reactivity with other CXC chemokine family members, thereby significantly reducing non-specific background interference and the risk of false positives during detection. This invention provides a high-performance, quality-controllable key tool for biological detection for non-diagnostic purposes, research on inflammatory mechanisms, and the development of related scientific reagents.

The invention provides high-specificity immunochromatography test paper as well as a preparation method and application thereof, and relates to the technical field of biological detection, the high-specificity immunochromatography test paper sequentially comprises a sample pad, a blood filtering pad and a combination pad which are lapped on a bottom plate in the chromatography direction; the blood filtering pad contains a pretreatment reagent, the pretreatment reagent comprises an anti-human RBC antibody, Tween-20 and bovine serum albumin, a blood filtering pad assembly is added between the combination pad and the detection pad of the immunochromatography test paper, and the blood filtering pad contains the pretreatment reagent, namely the anti-human RBC antibody, Tween-20 and bovine serum albumin, so that a sample is filtered to remove interfering substances; the reaction is homogenized; data show that the membrane surface background is free of redness, clean and free of interference in blood screen item detection, high specificity of products is guaranteed, and blocking agents are not used. The technical problem that nonspecific interference of an immunoreaction inhibitor is generated by using a blocking agent in immunochromatography test paper in the prior art is solved.

The invention provides a primer probe combination and a portable kit for African swine fever pathogen detection, and relates to the technical field of biological detection. The primer probe combination comprises an upstream primer, a downstream primer and a probe, the nucleotide sequence of the upstream primer is as shown in SEQ ID NO.7; the nucleotide sequence of the downstream primer is as shown in SEQ ID NO.8; and the nucleotide sequence of the probe is as shown in SEQ ID NO. 9. The primer probe combination adopts a specific sequence obtained by screening SEQ ID NO.7-9, the detection sensitivity reaches 1 copies / T, and non-specific amplification is avoided. Through double labeling of biotin and a fluorophore and modification of tetrahydrofuran and a blocking group, the group is suitable for isothermal amplification and lateral chromatography technologies, visual color development of a specific amplification product can be realized without a variable-temperature instrument, and the group is suitable for low-cost field rapid detection.

The present application relates to the technical field of clinical in vitro detection reagent, especially relates to reagent combination and its application in eliminating MALB reagent non-specific interference detection. When MALB reagent is calibrated at 0 point with purified water, and normal human urine sample is tested on a biochemical instrument, the test value can be 0 or negative, especially when the concentration of urine is 0 mg / L-5 mg / L, the test value is basically 0. The present application selects suitable Malb antibody and suitable antibody feeding amount to improve the sensitivity of reagent, and selects suitable background solution in the reaction system to reduce the non-specific interference of MALB reagent. Not only the problem of 0 or negative sample value is effectively improved, but also the detection accuracy is improved, which has important significance for improving the accuracy of MALB reagent test sample. The reagent combination provided by the present application has good clinical application and large-scale industrial production prospect.

This invention relates to the field of biotechnology, and more particularly to a biomarker, kit, and application for the diagnosis of pancreatic malignant tumors. The biomarker comprises aldehyde-ketone reductase 1B10 protein and carbohydrate antigen 19-9 protein. This biomarker is a secreted serum protein that can specifically distinguish PDAC patients from normal individuals, and from individuals with benign pancreatic diseases, exhibiting high specificity without significant non-specific elevation interference. Combined detection with CA199 can synergistically enhance diagnostic efficacy, significantly reducing the rate of missed diagnoses and misdiagnoses. Simultaneously, this biomarker can assess the postoperative tumor resection effect in PDAC patients, predict whether curative resection is achieved, and provide an effective target for postoperative prognostic monitoring.

The present application relates to the technical field of bioinformatics and drug evaluation, and particularly relates to a method for constructing an organoid drug sensitivity evaluation model based on multi-omics fusion, comprising synchronously collecting morphokinetic time sequence images and multi-time point single-cell multi-omics data of organoids, obtaining paired morphological and molecular dynamic data, extracting cell state factors through coupled non-negative tensor decomposition, constructing a non-equilibrium free energy landscape under drug disturbance, quantifying the loss degree of molecular system robustness from two dimensions of geometric deformation and topological structure, detecting cross-scale causal relationships and constructing a drug disturbance entropy index. In the present application, the drug effect is evaluated from the physical nature of the loss of biological system robustness, replacing the traditional correlation analysis method, realizing the unification of quantitative evaluation of drug sensitivity and explanation of the mechanism of action, effectively distinguishing drug specific action and non-specific stress, and being suitable for personalized tumor treatment and new drug research and development.

The invention discloses a novel Fc effect eliminated framework flow antibody, and belongs to the technical field of biological medicine. The antibody comprises a mutation combination of L234A, L235A, P238S and D265A in a heavy chain CH2 region, and can further comprise S267E and L328F mutations, so that the Fc receptor binding capacity is effectively reduced. The type of the antibody can be selected from multiple forms of scFv-Fc, (scFv) 2-Fc, scFv / scFv-Fc, Fab / scFv-Fc and the like. The invention also provides a nucleic acid sequence for coding the antibody and a preparation method of the antibody. The preparation method comprises the following steps: introducing specific mutation into a CH2 region of recombinant rabbit IgG, and expressing and purifying in a mammal expression system to obtain the antibody. When the antibody is applied to a flow cytometry detection reagent, a non-specific background signal caused by Fc receptor combination can be effectively eliminated, and the detection specificity and accuracy are improved.

The application provides a prognosis risk stratification prediction method for lymph node tumor residue, and belongs to the technical field of risk prediction, and comprises the following steps: acquiring lymph node HE staining sections and immunohistochemical labeling sections, automatically identifying a tumor region of interest by using a U-Net++ network, removing background noise and non-specific staining interference based on a self-adaptive threshold segmentation algorithm, extracting information in four dimensions, and forming a standardized extracted information set; fusing and mapping the extracted information set into a 256-dimensional feature vector set, inputting each vector into a dynamic integrated prediction model, and outputting stratified differential expression of each vector and stratified comprehensive expression of the vector set; determining a risk level based on quantitative threshold values of the stratified differential expression and comparative analysis of risk probabilities of the stratified comprehensive expression, and constructing a multi-dimensional dynamic weight decision model in combination with patient self-state indexes to formulate a personalized scheme. Through multi-modal feature extraction, dynamic integrated modeling and personalized decision-making, precise risk stratification and treatment scheme customization are realized.

The invention discloses a chiral metal organic framework material as well as a preparation method and application thereof, relates to the technical field of medical nano materials, and solves the problems of insufficient targeting specificity and poorer stability of an existing Parkinson's disease treatment drug. The preparation method comprises the following steps: dissolving ZrOCl2. 8H2O, Cu-TCCP and benzoic acid in DMF (Dimethyl Formamide), adding a cysteine aqueous solution, reacting at 30-70 DEG C, heating to 80-120 DEG C, and reacting; and centrifugally collecting a precipitation product, and washing and centrifuging the precipitation product through DMF and ultrapure water to obtain the chiral metal organic framework material. The material has the advantages of good stability, high biocompatibility, simple preparation, low cost, easy amplification and industrial production, overcomes the defects of poor stability, low bioavailability, strong non-specific effect and the like of the traditional alpha-syn inhibitor, and provides a new strategy and an efficient candidate material for early intervention and treatment of Parkinson's disease.

The application provides a method for synchronously detecting multiple cell death modes in a tissue slice based on multiplex immunofluorescence, and belongs to the technical field of biological detection. The application realizes the synchronous labeling and visualization of multiple cell death modes in a single tissue slice, significantly improves the detection efficiency and saves precious samples; by integrating key biomarkers covering main cell death modes in the same detection system, a self-defined interpretation scheme based on multi-marker expression combination is constructed, effectively reducing the error caused by non-specific expression of a single marker, improving the reliability and rationality of the death mode classification, and providing a general solution for rapid screening of complex cell death networks. The application is suitable for anticancer drug efficacy evaluation, combination drug regimen screening and disease mechanism research, and has important scientific research value and clinical conversion prospect.

The invention discloses an ultra-inductive signal amplifier based on hairpin self-cleaning and a detection method thereof, and belongs to the technical field of biosensing, the core component of the ultra-inductive signal amplifier based on hairpin self-cleaning is gold nanoparticle (AuNPs) conjugate TS (at) WS (at) AuNPs coupled with a track chain TS and a self-cleaning walking chain WS. The technology fundamentally solves the problem of background noise caused by physical residues of the non-activated probe and non-specific action, realizes nearly zero-background ultra-high-specificity detection, retains the strong signal amplification capability of a DNA walking machine, and is suitable for ultra-sensitive and high-reliability quantification of ultra-low-abundance targets in complex samples such as blood, tissue fluid and the like.

The application belongs to the technical field of sewage detection, and provides a norovirus GI and GII double genotype synchronous quantitative detection method, which realizes synchronous detection and absolute quantification of norovirus GI and GII in the same reaction tube, does not need to rely on a standard curve, and avoids errors caused by batch differences of standard products; in terms of primer and probe design, the constructed detection system shows high specificity, and even under the coexistence condition of other viruses with close genetic relationship, no non-specific amplification occurs; through gradient dilution experiment verification, the digital PCR method shows good linear response in a wide dynamic range, excellent linear correlation, low repeat variation coefficient, and shows excellent detection consistency and stability; the droplet generation performance is stable, the effective droplet number is always maintained at more than 19500, and the reliability of the quantitative result is ensured.

The invention provides a primer probe combination, a kit, a nucleic acid detection method and application, and relates to the technical field of biochemical detection. The primer probe combination comprises a first primer pair and a first probe, wherein the first primer pair and the first probe are used for specifically amplifying pseudomonas aeruginosa; the second primer pair and the second probe are used for specifically amplifying enterococcus; the third primer pair and the third probe are used for specifically amplifying staphylococcus aureus; the fourth primer pair and the fourth probe are used for specifically amplifying the salmonella enterica. According to the primer and probe combination, a specific nucleotide sequence is utilized, efficient and accurate recognition of pseudomonas aeruginosa, enterococcus, staphylococcus aureus and salmonella enterococcus is achieved in a complex intestinal environment, and non-specific interference is effectively avoided; meanwhile, synchronous quantitative detection of four pathogens is supported, the detection efficiency is remarkably improved, and an accurate and sensitive detection means is provided for rapid clinical evaluation of flora conditions.

The application belongs to the technical field of biological medicine. More specifically, it relates to a preparation and application of in-situ imaging DNA-PROTAC based on strand displacement activation. The novel DNA-PROTAC provided by the application is designed by three modules, which are respectively recruitment module A (E3 ligase ligand-linker-clicking group), locking module B (aptamer-shielded chain double-stranded complex) and activation module C (DNA single strand), three physically separated components, so that the degradation activity is completely silent in the delivery stage. Only after the drug reaches the target area, the in-situ assembly of recruitment module A and locking module B can be triggered by adding activation module C to trigger the strand displacement reaction, thereby effectively avoiding the non-specific activity of traditional degrading agents in the whole body circulation, and significantly reducing the off-target toxicity. In addition, the application converts the large conjugate into multiple independent components with medium and small molecular weights by physical splitting, overcoming the macromolecular delivery barrier.

The utility model provides a sample adding and smearing device for a syphilis non-specific antibody detection test, relates to the technical field of medical instruments, and aims to solve the problems that the device is inconvenient to smear and completely spread samples on different reaction cards at the same time, and when the sample size is large, a long time difference exists between early-stage sample adding and later-stage sample adding, so that the time difference is large. The device comprises a suction tube and a sample adding tube, wherein the suction tube is arranged on the suction tube; a group of fixing blocks are slidably mounted at the outer end of the suction tube, a group of pistons are slidably mounted in the suction tube, and the fixing blocks at the outer end of the suction tube are inserted into limiting grooves in the top of the movable frame; according to the reaction card smearing device, samples on different reaction cards can be conveniently smeared at the same time and completely spread, the use efficiency of the device is effectively improved, the smearing plate can be conveniently and automatically fixed at the horizontal position, and the use effect of the device is further improved.

The invention discloses a reagent, a kit and a detection method for free light chain detection, and relates to the technical field of detection kits, the reagent comprises the following components: a solid phase carrier surface marked with an F (ab ') 2 antibody fragment; the liquid-phase reaction liquid comprises a composite blocking agent for inhibiting non-specific reaction of endogenous interferents; wherein the F (ab ') 2 antibody fragment and the composite blocking agent act together to improve the detection specificity and reaction linearity. The problems that non-specific reaction is caused by an antibody Fc segment and an endogenous interferent when a latex enhanced immunoturbidimetric assay is used for detecting free light chains, existing means cannot eradicate the non-specific reaction, detection linearity is abnormal, and specificity is low are solved, the solid phase carrier marked with the F (ab ') 2 antibody segment and the composite blocking agent are used, and the solid phase carrier marked with the F (ab') 2 antibody segment and the composite blocking agent have a synergistic effect; closed-loop protection is formed from two dimensions of eliminating self interference of the antibody and shielding exogenous interference of the sample, and compared with an antibody optimization or interference shielding means, the combination targeting and detection specificity of a target analyte are synergistically improved.

The present invention addresses the problem of providing: a method for immunologically detecting a detection target substance having a sugar chain in a biological sample, in which the occurrence of a non-specific reaction is suppressed; a method for suppressing a non-specific reaction in a method for immunologically detecting a detection target substance having a sugar chain in a biological sample; a fucose-containing composition; and a reagent kit. According to the present invention, there is provided a method for immunologically detecting a detection target substance having a sugar chain in a biological sample, the method including reacting lectin with the detection target substance in the presence of fucose.

The application discloses a kind of chronic non-specific lumbar pain treatment data analysis method and device, it is related to medical data analysis processing technical field.Processing method includes: obtaining patient data to be treated;Acupoint graph is handled by segmentation, and local acupoint graph is obtained;According to individual difference data and the individual difference model constructed, the individual difference influence factor data of patient to be treated is obtained, according to individual difference influence factor data and individual difference factor, corresponding individual difference correction factor is obtained;Local acupoint graph is adjusted by optimizing through individual difference correction factor, and acupoint image data is obtained, acupoint analysis coefficient is obtained based on acupoint image data to generate acupoint visual feedback report, and acupoint analysis coefficient is used to quantitatively analyze the acupoint situation of patient to be treated.The technical effect of more accurately analyzing acupoint related treatment data can be achieved by using the application.

The invention provides an application of a serum exosome lncRNA in preparation of a detection product for immune checkpoint inhibitor associated pneumonia, and the serum exosome lncRNA is TTC9-DT, or TTC9-DT and ITGA2-AS1. The invention also provides an application of the serum exosome lncRNA in preparation of a detection product for immune checkpoint inhibitor associated pneumonia. By using the serum exosome lncRNA disclosed by the invention, the sensitivity, the specificity and the accuracy of immune checkpoint inhibitor-related pneumonia diagnosis can be remarkably improved, and compared with a clinical conventional non-specific blood index, the serum exosome lncRNA disclosed by the invention has a better diagnosis effect. In addition, detection can be carried out in a liquid biopsy mode, the method has the advantages of being minimally invasive, capable of achieving real-time monitoring and the like, a detection reagent is low in cost and high in universality, efficient clinical diagnosis and identification can be carried out, the early diagnosis rate is increased, and the method has high clinical application value and wide application prospects.